WTA
APGE icon

Washington Trust Advisors’s Apogee Therapeutics APGE Stock Holding History

Washington Trust Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-96
Closed -$3.81K – 592
2025
Q3 		$3.81K Hold
96
– – ﹤0.01% 637
2025
Q2 		$4.17K Hold
96
– – ﹤0.01% 584
2025
Q1 		$3.59K Hold
96
– – ﹤0.01% 578
2024
Q4 		$4.35K Hold
96
– – ﹤0.01% 582
2024
Q3 		$5.64K Hold
96
– – ﹤0.01% 556
2024
Q2 		$3.78K Hold
96
– – ﹤0.01% 590
2024
Q1 		$6.38K Hold
96
– – ﹤0.01% 540
2023
Q4 		$2.68K Hold
96
– – ﹤0.01% 631
2023
Q3 		$2.04K Buy
+96
New +$2.12K ﹤0.01% 640

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Washington Trust Advisors's APGE Position: Q4 2025 in Review

Washington Trust Advisors sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 96 shares — an estimated $3.81K sold.

Washington Trust Advisors first reported a position in APGE in Q3 2023 and held it in 9 quarters. The position peaked at $6.38K in Q1 2024. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Washington Trust Advisors reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 96 Apogee Therapeutics shares in Q4 2025, an estimated $3.81K.
  • Washington Trust Advisors first reported a position in Apogee Therapeutics in Q3 2023 and held it in 9 quarters.
  • Washington Trust Advisors's Apogee Therapeutics position peaked at $6.38K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.